Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.26
2
Healthy long term growth as Operating profit has grown by an annual rate 35.27%
3
Positive results in Mar 25
4
With ROE of 7.1, it has a attractive valuation with a 1.3 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
PKR 16,687 Million (Small Cap)
20.00
NA
1.04%
0.10
7.94%
1.32
Revenue and Profits:
Net Sales:
5,092 Million
(Quarterly Results - Mar 2025)
Net Profit:
248 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.34%
0%
20.34%
6 Months
4.77%
0%
4.77%
1 Year
50.68%
0%
50.68%
2 Years
172.35%
0%
172.35%
3 Years
72.27%
0%
72.27%
4 Years
24.8%
0%
24.8%
5 Years
66.96%
0%
66.96%
Ferozsons Laboratories Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
25.99%
EBIT Growth (5y)
26.55%
EBIT to Interest (avg)
12.26
Debt to EBITDA (avg)
0.80
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
1.08
Tax Ratio
34.23%
Dividend Payout Ratio
22.39%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.80%
ROE (avg)
9.47%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.48
EV to EBIT
9.57
EV to EBITDA
6.63
EV to Capital Employed
1.42
EV to Sales
1.07
PEG Ratio
0.90
Dividend Yield
1.66%
ROCE (Latest)
14.83%
ROE (Latest)
7.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
5,091.90
4,731.00
7.63%
Operating Profit (PBDIT) excl Other Income
756.50
674.20
12.21%
Interest
109.70
171.50
-36.03%
Exceptional Items
0.00
0.00
Consolidate Net Profit
247.80
177.60
39.53%
Operating Profit Margin (Excl OI)
96.00%
97.20%
-0.12%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is 7.63% vs 4.46% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 39.53% vs -26.31% in Dec 2024
Annual Results Snapshot (Consolidated) - Jun'24
Jun'24
Jun'23
Change(%)
Net Sales
15,854.80
11,457.20
38.38%
Operating Profit (PBDIT) excl Other Income
2,108.00
1,295.50
62.72%
Interest
670.60
302.50
121.69%
Exceptional Items
49.70
5.00
894.00%
Consolidate Net Profit
755.50
296.20
155.06%
Operating Profit Margin (Excl OI)
99.00%
71.80%
2.72%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2024 is 38.38% vs 22.80% in Jun 2023
Consolidated Net Profit
YoY Growth in year ended Jun 2024 is 155.06% vs -62.50% in Jun 2023
About Ferozsons Laboratories Ltd. 
Ferozsons Laboratories Ltd.
Pharmaceuticals & Biotechnology
Ferozsons Laboratories Limited is a Pakistan-based holding company, which is primarily engaged in importing, manufacturing and sale of pharmaceuticals products. The Company offers a range of branded generics and in-licensed products in the areas of cardiology, oncology, gastroenterology, dermatology and anti-infective markets in the Pakistan. The Company's production capabilities include the manufacturing of tablets, capsules, syrups, suspensions, creams and ointments. Its products include Salazodine EC Tabs, Cimet Tablets and Suspension, Centaurus Tablets, Novapressin, Filgen Injection, Oxaltie Injection, Imuxgen Tablets, Anfogen Injection and Donataxel Injection, among others. The Company's subsidiaries include BF Biosciences Limited, which is engaged in the import, manufacturing and sale of pharmaceutical products and Farmacia, which is engaged in the sale and distribution of medicines and other related products.
Company Coordinates 
Company Details
197- A ,The Mall , RAWALPINDI None : 46000
Registrar Details






